Opinion|Videos|February 10, 2025
Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Advertisement
Video content above is prompted by the following:
- How do the treatment options evolve as a child ages?
- FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
- How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
- Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Vaccine schedule overhaul raises concerns about delayed protection and access, says Ravi Jhaveri, MD
2
Rethinking screen time for back to school
3
Building trust may be key to vaccine conversations with hesitant families
4
Back-to-school vaccinations: What pediatricians need to know for the back-to-school season
5